<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32676081</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Environmental Risk Factors for Sarcoidosis.</ArticleTitle>
        <Pagination>
          <StartPage>1340</StartPage>
          <MedlinePgn>1340</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1340</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.01340</ELocationID>
        <Abstract>
          <AbstractText>Sarcoidosis is a multisystem granulomatous disease that may affect any body organ. Sarcoidosis is associated with many environmental and occupational exposures. Because the exact immunopathogenesis of sarcoidosis is unknown, it is not known whether these exposures are truly causing sarcoidosis, rendering the immune system more susceptible to the development of sarcoidosis, exacerbating subclinical cases of sarcoidosis, or causing a granulomatous condition distinct from sarcoidosis. This manuscript outlines what is known about the immunopathogenesis of sarcoidosis and postulates mechanisms whereby these exposures could cause or exacerbate the disease. We also describe the varied environmental and occupational exposures that have been associated with sarcoidosis. This includes potential infectious exposures such as mycobacteria and Propionibacterium acnes, a skin commensal bacterium, as well as non-infectious environmental exposures including inhaled bioaerosols, metal dusts and products of combustion. Further insights concerning the relationship of environmental exposures to the development of sarcoidosis may have a major impact on the prevention and treatment of this enigmatic disease.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Judson.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Judson</LastName>
            <ForeName>Marc A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Albany Medical College, Albany, NY, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">antigen</Keyword>
        <Keyword MajorTopicYN="Y">environment</Keyword>
        <Keyword MajorTopicYN="Y">immunity</Keyword>
        <Keyword MajorTopicYN="Y">infection</Keyword>
        <Keyword MajorTopicYN="Y">sarcoidosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32676081</ArticleId>
        <ArticleId IdType="pmc">PMC7333358</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2020.01340</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. . Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. (2001) 164(10 Pt 1):1885–9. 10.1164/ajrccm.164.10.2104046</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/ajrccm.164.10.2104046</ArticleId>
            <ArticleId IdType="pubmed">11734441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. (2012) 29:119–27. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23461074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol. (2012) 3:411. 10.3389/fimmu.2012.00411</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2012.00411</ArticleId>
            <ArticleId IdType="pmc">PMC3538277</ArticleId>
            <ArticleId IdType="pubmed">23308075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zumla A, James DG. Granulomatous infections: etiology and classification. Clin Infect Dis. (1996) 23:146–58. 10.1093/clinids/23.1.146</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/clinids/23.1.146</ArticleId>
            <ArticleId IdType="pubmed">8816144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. (2012). 186:314–24. 10.1164/rccm.201203-0513CI</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201203-0513CI</ArticleId>
            <ArticleId IdType="pubmed">22679012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect. (1996) 104(Suppl. 5):945–7. 10.1289/ehp.96104s5945</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1289/ehp.96104s5945</ArticleId>
            <ArticleId IdType="pmc">PMC1469698</ArticleId>
            <ArticleId IdType="pubmed">8933039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. (1997) 336:1224–34. 10.1056/NEJM199704243361706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199704243361706</ArticleId>
            <ArticleId IdType="pubmed">9110911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. (2011) 183:573–81. 10.1164/rccm.201006-0865CI</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201006-0865CI</ArticleId>
            <ArticleId IdType="pmc">PMC3081278</ArticleId>
            <ArticleId IdType="pubmed">21037016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moller DR, Chen ES. Genetic basis of remitting sarcoidosis: triumph of the trimolecular complex?
Am J Respir Crit Care Med. (2002) 27:391–5. 10.1165/rcmb.2002-0164PS</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2002-0164PS</ArticleId>
            <ArticleId IdType="pubmed">12356571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broos CE, Koth LL, van Nimwegen M, Veen JCCM, Paulissen SMJ, Hamburg JP, et al. . Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J. (2018) 51:170112. 10.1183/13993003.01124-2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01124-2017</ArticleId>
            <ArticleId IdType="pubmed">29449421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis. (2002) 19:83–95. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12102613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du Bois R, Beirne PA, Anevlavis SE.
Genetics. In: Drent M, Costabel U. editors. Sarcoidosis: European Respiratory Monograph.
Sheffield: European respiroatry Society Journals Ltd;  (2005). p. 64–81. 10.1183/1025448x.00032005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/1025448x.00032005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, et al. . HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. (2003) 73:720–35. 10.1086/378097</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/378097</ArticleId>
            <ArticleId IdType="pmc">PMC1180597</ArticleId>
            <ArticleId IdType="pubmed">14508706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer AS, Hamzeh N, Maier LA. Sarcoidosis and chronic beryllium disease: similarities and differences. Semin Respir Crit Care Med. (2014) 35:316–29. 10.1055/s-0034-1377059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0034-1377059</ArticleId>
            <ArticleId IdType="pubmed">25007084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J. (2006) 27:1190–5. 10.1183/09031936.06.00112205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.06.00112205</ArticleId>
            <ArticleId IdType="pubmed">16540500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Fingerlin TE, et al. . Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med. (2011) 183:1680–8. 10.1164/rccm.201002-0254OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201002-0254OC</ArticleId>
            <ArticleId IdType="pmc">PMC3136994</ArticleId>
            <ArticleId IdType="pubmed">21471109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL, et al. . Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occup Environ Med. (2011) 68:842–8. 10.1136/oem.2010.064220</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/oem.2010.064220</ArticleId>
            <ArticleId IdType="pmc">PMC4347849</ArticleId>
            <ArticleId IdType="pubmed">21460389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA. (2000) 97:12717–22. 10.1073/pnas.220430797</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.220430797</ArticleId>
            <ArticleId IdType="pmc">PMC18830</ArticleId>
            <ArticleId IdType="pubmed">11050177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tinkle SS, Schwitters PW, Newman LS. Cytokine production by bronchoalveolar lavage cells in chronic beryllium disease. Environ Health Perspect. (1996) 104(Suppl. 5):969–71. 10.1289/ehp.96104s5969</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1289/ehp.96104s5969</ArticleId>
            <ArticleId IdType="pmc">PMC1469699</ArticleId>
            <ArticleId IdType="pubmed">8933043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James WE, Koutroumpakis E, Saha B, Nathani A, Saavedra L, Yucel RM, et al. . Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest. (2018) 154:349–56. 10.1016/j.chest.2018.02.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2018.02.003</ArticleId>
            <ArticleId IdType="pubmed">29453944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurata A, Terado Y, Izumi M, Fujioka Y, Franke FE. Where does the antigen of cutaneous sarcoidosis come from?
J Cutan Pathol. (2010) 37:211–21. 10.1111/j.1600-0560.2009.01309.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0560.2009.01309.x</ArticleId>
            <ArticleId IdType="pubmed">19615023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bordignon M, Rottoli P, Agostini C, Alaibac M. Adaptive immune responses in primary cutaneous sarcoidosis. Clin Dev Immunol. (2011) 2011:235142. 10.1155/2011/235142</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2011/235142</ArticleId>
            <ArticleId IdType="pmc">PMC3095245</ArticleId>
            <ArticleId IdType="pubmed">21603192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkman CC, Rouhani SJ, Srinivasan N, Engelhard VH. Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells. J Immunol. (2013) 191:2412–25. 10.4049/jimmunol.1300651</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300651</ArticleId>
            <ArticleId IdType="pmc">PMC3796582</ArticleId>
            <ArticleId IdType="pubmed">23926324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judson MA. A sarcoidosis clinician's perspective of MHC functional elements outside the antigen binding site. Hum Immunol. (2019) 80:85–9. 10.1016/j.humimm.2018.05.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humimm.2018.05.007</ArticleId>
            <ArticleId IdType="pubmed">29859205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossman MD, Thompson B, Frederick M, Iannuzzi MC, Rybicki BA, Pander JP, et al. . HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2008) 25:125–32. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19382531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zissel G, Muller-Quernheim J. Specific antigen(s) in sarcoidosis: a link to autoimmunity?
Eur Respir J. (2016) 47:707–9. 10.1183/13993003.01791-2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01791-2015</ArticleId>
            <ArticleId IdType="pubmed">26929312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Häggmark A, Hamsten C, Wiklundh E, Lindskog C, Mattsson C, Andersson E, et al. . Proteomic profiling reveals autoimmune targets in sarcoidosis. Am J Respir Crit Care Med. (2015) 191:574–83. 10.1164/rccm.201407-1341OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201407-1341OC</ArticleId>
            <ArticleId IdType="pubmed">25608002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchernev G, Lotti T, Cardoso JC, Kanazawa N, Guarneri C, Wollina U. Cancer, infection and disturbances of the integrity of tissue homeostasis: the most significant triggers for molecular mimicry and autoimmunity in dermatology?
Wien Med Wochenschr. (2014) 164:245–6. 10.1007/s10354-014-0280-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10354-014-0280-2</ArticleId>
            <ArticleId IdType="pubmed">24796584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchernev G, Wollina U. Bacterial antigens and molecular mimicry: the bridging common problematic link in the pathogenesis of sarcoidosis and sarcoid-like reactions: isn't it time to wake up?
Wien Med Wochenschr. (2014). 164:260–2. 10.1007/s10354-014-0283-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10354-014-0283-z</ArticleId>
            <ArticleId IdType="pubmed">24871544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinloch AJ, Kaiser Y, Wolfgeher D, Ai J, Eklund A, Clark MR, et al. . In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis. Front Immunol. (2018) 9:1516. 10.3389/fimmu.2018.01516</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01516</ArticleId>
            <ArticleId IdType="pmc">PMC6046378</ArticleId>
            <ArticleId IdType="pubmed">30038611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas M, Restrepo-Jimenez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, et al. . Molecular mimicry and autoimmunity. J Autoimmun. (2018) 95:100–23. 10.1016/j.jaut.2018.10.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2018.10.012</ArticleId>
            <ArticleId IdType="pubmed">30509385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grunewald J, Kaiser Y, Ostadkarampour M, Rivera NV, Vezzi F, Lötstedt B, et al. . T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. (2016) 47:898–909. 10.1183/13993003.01209-2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01209-2015</ArticleId>
            <ArticleId IdType="pubmed">26585430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eberhardt C, Thillai M, Parker R, Siddiqui N, Potiphar L, Goldin R, et al. . Proteomic analysis of kveim reagent identifies targets of cellular immunity in sarcoidosis. PLoS ONE. (2017) 12:e0170285. 10.1371/journal.pone.0170285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0170285</ArticleId>
            <ArticleId IdType="pmc">PMC5256960</ArticleId>
            <ArticleId IdType="pubmed">28114394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heyder T, Kohler M, Tarasova NK, Haag S, Rutishauser D, Rivera NV, et al. . Approach for identifying human leukocyte antigen (HLA)-DR bound peptides from scarce clinical samples. Mol Cell Proteomics. (2016) 15:3017–29. 10.1074/mcp.M116.060764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M116.060764</ArticleId>
            <ArticleId IdType="pmc">PMC5013314</ArticleId>
            <ArticleId IdType="pubmed">27452731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahlström J, Dengjel J, Winqvist O, Targoff I, Persson B, Duyar H, et al. . Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol. (2009) 133:353–63. 10.1016/j.clim.2009.08.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2009.08.008</ArticleId>
            <ArticleId IdType="pubmed">19786367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, et al. . Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. (2007) 117:3576–82. 10.1172/JCI32401</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI32401</ArticleId>
            <ArticleId IdType="pmc">PMC2045606</ArticleId>
            <ArticleId IdType="pubmed">17975675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontenot AP, Falta MT, Kappler JW, Dai S, McKee AS. Beryllium-induced hypersensitivity: genetic susceptibility and neoantigen generation. J Immunol. (2016) 196:22–7. 10.4049/jimmunol.1502011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1502011</ArticleId>
            <ArticleId IdType="pmc">PMC4685955</ArticleId>
            <ArticleId IdType="pubmed">26685315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobak S, Yilmaz H, Sever F, Duran A, Sen N, Karaarslan A. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis. (2014) 2014:351852. 10.1155/2014/351852</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/351852</ArticleId>
            <ArticleId IdType="pmc">PMC4281448</ArticleId>
            <ArticleId IdType="pubmed">25580285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, et al. . Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA. (2005) 102:7922–7. 10.1073/pnas.0501190102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0501190102</ArticleId>
            <ArticleId IdType="pmc">PMC1142372</ArticleId>
            <ArticleId IdType="pubmed">15894616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. (2018) 13:1076–82. 10.1016/j.jtho.2018.04.031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.04.031</ArticleId>
            <ArticleId IdType="pubmed">29763666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. . Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. (2017) 82:34–44. 10.1016/j.ejca.2017.05.032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.05.032</ArticleId>
            <ArticleId IdType="pubmed">28646772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. (2018) 9:227–40. 10.1177/2040622318790197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040622318790197</ArticleId>
            <ArticleId IdType="pmc">PMC6196636</ArticleId>
            <ArticleId IdType="pubmed">30364496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossides M, Grunewald J, Eklund A, Kullberg S, Di Giuseppe D, Askling J, et al. . Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. (2018) 52:1800385. 10.1183/13993003.00385-2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00385-2018</ArticleId>
            <ArticleId IdType="pubmed">29946010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin AM, Iannuzzi MC, Montgomery CG, Trudeau S, Datta I, McKeigue P, et al. . Association of ANXA11 genetic variation with sarcoidosis in African Americans and European Americans. Genes Immun. (2013) 14:13–8. 10.1038/gene.2012.48</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gene.2012.48</ArticleId>
            <ArticleId IdType="pmc">PMC3595044</ArticleId>
            <ArticleId IdType="pubmed">23151485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrianto I, Lin CP, Hale JJ, Levin AM, Datta I, Parker R, et al. . Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS ONE. (2012) 7:e43907. 10.1371/journal.pone.0043907</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0043907</ArticleId>
            <ArticleId IdType="pmc">PMC3428296</ArticleId>
            <ArticleId IdType="pubmed">22952805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morais A, Lima B, Peixoto MJ, Alves H, Marques A, Delgado L. BTNL2 gene polymorphism associations with susceptibility and phenotype expression in sarcoidosis. Respir Med. (2012) 106:1771–7. 10.1016/j.rmed.2012.08.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2012.08.009</ArticleId>
            <ArticleId IdType="pubmed">23017494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esteves T, Aparicio G, Garcia-Patos V. Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis. BMC Pulm Med. (2016) 16:165. 10.1186/s12890-016-0332-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12890-016-0332-z</ArticleId>
            <ArticleId IdType="pmc">PMC5126827</ArticleId>
            <ArticleId IdType="pubmed">27894280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang C, Huang H, Xu Z. Immunological evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. PLoS ONE. (2016) 11:e0154716. 10.1371/journal.pone.0154716</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0154716</ArticleId>
            <ArticleId IdType="pmc">PMC4968811</ArticleId>
            <ArticleId IdType="pubmed">27479700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Eom M, Kim SH, Wang HY, Lee H, Choi EH. Identification of Mycobacterium tuberculosis and non-tuberculous mycobacteria from cutaneous sarcoidosis lesions by reverse blot hybridization assay. J Dermatol. (2019) 46:917–21. 10.1111/1346-8138.15042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1346-8138.15042</ArticleId>
            <ArticleId IdType="pubmed">31392741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goyal B, Sheikh JA, Agarwal R, Verma I. Levels of circulating immune complexes containing Mycobacterium Tuberculosis-specific antigens in pulmonary tuberculosis and sarcoidosis patients. Indian J Med Microbiol. (2017) 35:290–2. 10.4103/0255-0857.209569</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0255-0857.209569</ArticleId>
            <ArticleId IdType="pubmed">28681824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotsinger JE, Celada LJ, Polosukhin VV, Atkinson JB, Drake WP. Molecular analysis of sarcoidosis granulomas reveals antimicrobial targets. Am J Respir Cell Mol Biol. (2016) 55:128–34. 10.1165/rcmb.2015-0212OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2015-0212OC</ArticleId>
            <ArticleId IdType="pmc">PMC4942207</ArticleId>
            <ArticleId IdType="pubmed">26807608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T, et al. . Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. (2002) 40:198–204. 10.1128/JCM.40.1.198-204.2002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.40.1.198-204.2002</ArticleId>
            <ArticleId IdType="pmc">PMC120089</ArticleId>
            <ArticleId IdType="pubmed">11773116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milman N, Lisby G, Friis S, Kemp L. Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study. Sarcoidosis Vasc Diffuse Lung Dis. (2004) 21:25–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15127971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. . Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. (2005) 201:755–67. 10.1084/jem.20040429</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20040429</ArticleId>
            <ArticleId IdType="pmc">PMC2212832</ArticleId>
            <ArticleId IdType="pubmed">15753209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ES, Wahlström J, Song Z, Willett MH, Wikén M, Yung RC, et al. . T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. (2008) 181:8784–96. 10.4049/jimmunol.181.12.8784</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.12.8784</ArticleId>
            <ArticleId IdType="pmc">PMC2700300</ArticleId>
            <ArticleId IdType="pubmed">19050300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake WP, Dhason MS, Nadaf M, Shepherd BE, Vadivelu S, Hajizadeh R, et al. . Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun. (2007) 75:527–30. 10.1128/IAI.00732-06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00732-06</ArticleId>
            <ArticleId IdType="pmc">PMC1828402</ArticleId>
            <ArticleId IdType="pubmed">17088357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oswald-Richter KA, Culver DA, Hawkins C, Hajizadeh R, Abraham S, Shepherd BE, et al. . Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. (2009) 77:3740–8. 10.1128/IAI.00142-09</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00142-09</ArticleId>
            <ArticleId IdType="pmc">PMC2738026</ArticleId>
            <ArticleId IdType="pubmed">19596780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homma JY, Abe C, Chosa H, Ueda K, Saegusa J, Nakayama M, et al. . Bacteriological investigation on biopsy specimens from patients with sarcoidosis. Jpn J Exp Med. (1978) 48:251–5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">713130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe C, Iwai K, Mikami R, Hosoda Y. Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A. (1984) 256:541–7. 10.1016/S0174-3031(84)80032-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0174-3031(84)80032-3</ArticleId>
            <ArticleId IdType="pubmed">6377763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagata K, Eishi Y, Uchida K, Yoneda K, Hatanaka H, Yasuhara T, et al. . Immunohistochemical detection of propionibacterium acnes in the retinal granulomas in patients with ocular sarcoidosis. Sci Rep. (2017) 7:15226. 10.1038/s41598-017-15710-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-15710-0</ArticleId>
            <ArticleId IdType="pmc">PMC5680245</ArticleId>
            <ArticleId IdType="pubmed">29123243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki Y, Uchida K, Takemura T, Sekine M, Tamura T, Furukawa A, et al. . Propionibacterium acnes-derived insoluble immune complexes in sinus macrophages of lymph nodes affected by sarcoidosis. PLoS ONE. (2018) 13:e0192408. 10.1371/journal.pone.0192408</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0192408</ArticleId>
            <ArticleId IdType="pmc">PMC5798840</ArticleId>
            <ArticleId IdType="pubmed">29401490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hajizadeh R, Sato H, Carlisle J, Nadaf MT, Evans W, Shepherd BE, et al. . Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol. (2007) 27:445–54. 10.1007/s10875-007-9080-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-007-9080-4</ArticleId>
            <ArticleId IdType="pmc">PMC3962023</ArticleId>
            <ArticleId IdType="pubmed">17357846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A, Zwolska Z, Izycka-Swieszewska E, Augustynowicz-Kopec E, et al. . Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. (2006) 44:3448–51. 10.1128/JCM.01433-06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01433-06</ArticleId>
            <ArticleId IdType="pmc">PMC1594733</ArticleId>
            <ArticleId IdType="pubmed">16954298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, et al. . Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol. (2007) 150:460–8. 10.1111/j.1365-2249.2007.03510.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2007.03510.x</ArticleId>
            <ArticleId IdType="pmc">PMC2219367</ArticleId>
            <ArticleId IdType="pubmed">17924974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakata Y, Ejiri T, Kishi T, Mori Y, Hioka T, Kataoka M, et al. . Alveolar lymphocyte proliferation induced by Propionibacterium acnes in sarcoidosis patients. Acta Med Okayama. (1986) 40:257–64. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3024453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furusawa H, Suzuki Y, Miyazaki Y, Inase N, Eishi Y. Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respir Investig. (2012) 50:104–9. 10.1016/j.resinv.2012.07.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.resinv.2012.07.001</ArticleId>
            <ArticleId IdType="pubmed">23021769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terčelj M, Stopinšek S, Ihan A, Salobir B, Simčič S, Wraber B, et al. . In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis. Clin Exp Immunol. (2011) 166:87–93. 10.1111/j.1365-2249.2011.04456.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2011.04456.x</ArticleId>
            <ArticleId IdType="pmc">PMC3193923</ArticleId>
            <ArticleId IdType="pubmed">21910725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suchankova M, Paulovicova E, Paulovicova L, Majer I, Tedlova E, Novosadova H, et al. . Increased antifungal antibodies in bronchoalveolar lavage fluid and serum in pulmonary sarcoidosis. Scand J Immunol. (2015) 81:259–64. 10.1111/sji.12273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/sji.12273</ArticleId>
            <ArticleId IdType="pubmed">25641379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishihara M, Ohno S, Ono H, Isogai E, Kimura K, Isogai H, et al. . Seroprevalence of anti-Borrelia antibodies among patients with confirmed sarcoidosis in a region of Japan where Lyme borreliosis is endemic. Graefes Arch Clin Exp Ophthalmol. (1998) 236:280–4. 10.1007/s004170050078</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004170050078</ArticleId>
            <ArticleId IdType="pubmed">9561361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Ma D, Luo W, Zhu Y. Detection of Borrelia burgdorferi DNA in granulomatous tissues from patients with sarcoidosis using polymerase chain reaction in situ technique. Chin Med Sci J. (1996) 11:220–3. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9387386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lian W, Luo W. Borrelia burgdorferi DNA in biological samples from patients with sarcoidosis using the polymerase chain reaction technique. Chin Med Sci J. (1995) 10:93–5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7647327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, et al. . Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2013) 30:201–11. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3929334</ArticleId>
            <ArticleId IdType="pubmed">24284293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. . Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. (2013) 149:1040–9. 10.1001/jamadermatol.2013.4646</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2013.4646</ArticleId>
            <ArticleId IdType="pmc">PMC3927541</ArticleId>
            <ArticleId IdType="pubmed">23863960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steen T, English JC. Oral minocycline in treatment of cutaneous sarcoidosis. JAMA Dermatol. (2013) 149:758–60. 10.1001/jamadermatol.2013.2977</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2013.2977</ArticleId>
            <ArticleId IdType="pubmed">23783160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. (2001) 137:69–73. 10.1001/archderm.137.1.69</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archderm.137.1.69</ArticleId>
            <ArticleId IdType="pubmed">11176663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki E, Ando M, Fukami T, Nureki S, Eishi Y, Kumamoto T. Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect?
Clin Rheumatol. (2008) 27:1195–7. 10.1007/s10067-008-0903-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-008-0903-3</ArticleId>
            <ArticleId IdType="pubmed">18458989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takemori N, Nakamura M, Kojima M, Eishi Y. Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. J Med Case Rep. (2014) 8:15. 10.1186/1752-1947-8-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1752-1947-8-15</ArticleId>
            <ArticleId IdType="pmc">PMC3916803</ArticleId>
            <ArticleId IdType="pubmed">24428939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tercelj M, Salobir B, Zupancic M, Rylander R. Antifungal medication is efficient in the treatment of sarcoidosis. Ther Adv Respir Dis. (2011) 5:157–62. 10.1177/1753465811401648</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1753465811401648</ArticleId>
            <ArticleId IdType="pubmed">21436319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inaoka PT, Shono M, Kamada M, Espinoza JL. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci. (2019) 26:45. 10.1186/s12929-019-0537-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12929-019-0537-6</ArticleId>
            <ArticleId IdType="pmc">PMC6558716</ArticleId>
            <ArticleId IdType="pubmed">31182092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinoza JL, Minami M. Sensing bacterial-induced DNA damaging effects via natural killer group 2 member D immune receptor: from dysbiosis to autoimmunity and carcinogenesis. Front Immunol. (2018) 9:52. 10.3389/fimmu.2018.00052</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00052</ArticleId>
            <ArticleId IdType="pmc">PMC5788971</ArticleId>
            <ArticleId IdType="pubmed">29422899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. (2018) 44:34–40. 10.1016/j.mib.2018.07.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mib.2018.07.003</ArticleId>
            <ArticleId IdType="pmc">PMC6435260</ArticleId>
            <ArticleId IdType="pubmed">30036705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa AN, Costa FMD, Campos SV, Salles RK, Athanazio RA. The pulmonary microbiome: challenges of a new paradigm. J Bras Pneumol. (2018) 44:424–32. 10.1590/s1806-37562017000000209</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/s1806-37562017000000209</ArticleId>
            <ArticleId IdType="pmc">PMC6467588</ArticleId>
            <ArticleId IdType="pubmed">30066739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulaiman I, Wu BG, Li Y, Scott AS, Malecha P, Scaglione B, et al. . Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J. (2018) 52:1800810. 10.1183/13993003.00810-2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00810-2018</ArticleId>
            <ArticleId IdType="pubmed">30093571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garzoni C, Brugger SD, Qi W, Wasmer S, Cusini A, Dumont P, et al. . Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax. (2013) 68:1150–6. 10.1136/thoraxjnl-2012-202917</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thoraxjnl-2012-202917</ArticleId>
            <ArticleId IdType="pmc">PMC3841796</ArticleId>
            <ArticleId IdType="pubmed">23945167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke EL, Lauder AP, Hofstaedter CE, Hwang Y, Fitzgerald AS, Imai I, et al. . Microbial Lineages in Sarcoidosis. A Metagenomic Analysis Tailored for Low-Microbial Content Samples. Am J Respir Crit Care Med. (2018) 197:225–34. 10.1164/rccm.201705-0891OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201705-0891OC</ArticleId>
            <ArticleId IdType="pmc">PMC5768903</ArticleId>
            <ArticleId IdType="pubmed">28846439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmermann A, Knecht H, Häsler R, Zissel G, Gaede KI, Hofmann S, et al. . Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota. Eur Respir J. (2017) 50:1600746. 10.1183/13993003.00746-2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00746-2016</ArticleId>
            <ArticleId IdType="pubmed">29242257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scher JU, Joshua V, Artacho A, Abdollahi-Roodsaz S, Öckinger J, Kullberg S, et al. . The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome. (2016) 4:60. 10.1186/s40168-016-0206-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-016-0206-x</ArticleId>
            <ArticleId IdType="pmc">PMC5114783</ArticleId>
            <ArticleId IdType="pubmed">27855721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. (1986) 123:840–5. 10.1093/oxfordjournals.aje.a114313</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a114313</ArticleId>
            <ArticleId IdType="pubmed">3962966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demirkok SS, Basaranoglu M, Coker E, Karayel T. Seasonality of the onset of symptoms, tuberculin test anergy and Kveim positive reaction in a large cohort of patients with sarcoidosis. Respirology. (2007) 12:591–3. 10.1111/j.1440-1843.2007.01062.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1843.2007.01062.x</ArticleId>
            <ArticleId IdType="pubmed">17587428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilsher ML. Seasonal clustering of sarcoidosis presenting with erythema nodosum. Eur Respir J. (1998) 12:1197–9. 10.1183/09031936.98.12051197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.98.12051197</ArticleId>
            <ArticleId IdType="pubmed">9864021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fité E, Alsina JM, Mañá J, Pujol R, Ruiz J, Morera J. Epidemiology of sarcoidosis in Catalonia: 1979-1989. Sarcoidosis Vasc Diffuse Lung Dis. (1996) 13:153–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8893385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta D, Agarwal R, Aggarwal AN. Seasonality of sarcoidosis: the 'heat' is on. Sarcoidosis Vasc Diffuse Lung Dis. (2013) 30:241–3. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24284300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ungprasert P, Crowson CS, Matteson EL. Seasonal variation in incidence of sarcoidosis: a population-based study, 1976-2013. Thorax. (2016) 71:1164–6. 10.1136/thoraxjnl-2016-209032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thoraxjnl-2016-209032</ArticleId>
            <ArticleId IdType="pmc">PMC5316382</ArticleId>
            <ArticleId IdType="pubmed">27539620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson TT, Plant BJ, Henry MT, Bredin CP. Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996-2005. Sarcoidosis Vasc Diffuse Lung Dis. (2010) 27:111–20. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21319593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosoda Y, Sasagawa S, Yamaguchi T. Sarcoidosis and tuberculosis: epidemiological similarities and dissimilarities. A review of a series of studies in a Japanese work population. (1941-1996) and the general population (1959-1984). Sarcoidosis Vasc Diffuse Lung Dis. (2004). 21:85–93. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15281429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonough C, Gray GC. Risk factors for sarcoidosis hospitalization among U.S. Navy and Marine Corps personnel, 1981 to 1995. Mil Med. (2000). 165:630–2. 10.1093/milmed/165.8.630</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/milmed/165.8.630</ArticleId>
            <ArticleId IdType="pubmed">10957860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajdasz DK, Judson MA, Mohr LC, Lackland DT. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am J Epidemiol. (1999) 150:271–8. 10.1093/oxfordjournals.aje.a009998</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a009998</ArticleId>
            <ArticleId IdType="pubmed">10430231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowalska M, Niewiadomska E, Zejda JE. Epidemiology of sarcoidosis recorded in 2006-2010 in the Silesian voivodeship on the basis of routine medical reporting. Ann Agric Environ Med. (2014) 21:55–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24738497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J. (2010) 35:1088–97. 10.1183/09031936.00197808</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00197808</ArticleId>
            <ArticleId IdType="pubmed">19897550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prezant DJ, Dhala A, Goldstein A, Janus D, Ortiz F, Aldrich TK, et al. . The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest. (1999) 116:1183–93. 10.1378/chest.116.5.1183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.116.5.1183</ArticleId>
            <ArticleId IdType="pubmed">10559074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kern DG, Neill MA, Wrenn DS, Varone JC. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis. (1993) 148(4 Pt 1):974–80. 10.1164/ajrccm/148.4_Pt_1.974</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/ajrccm/148.4_Pt_1.974</ArticleId>
            <ArticleId IdType="pubmed">8214953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorham ED, Garland CF, Garland FC, Kaiser K, Travis WD, Centeno JA. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975-2001. Chest. (2004) 126:1431–8. 10.1378/chest.126.5.1431</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.126.5.1431</ArticleId>
            <ArticleId IdType="pubmed">15539709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. . A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. (2004) 170:1324–30. 10.1164/rccm.200402-249OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200402-249OC</ArticleId>
            <ArticleId IdType="pubmed">15347561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, et al. . Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med. (2005) 47:226–34. 10.1097/01.jom.0000155711.88781.91</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.jom.0000155711.88781.91</ArticleId>
            <ArticleId IdType="pubmed">15761318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucera GP, Rybicki BA, Kirkey KL, Coon SW, Major ML, Maliarik MJ, et al. . Occupational risk factors for sarcoidosis in African-American siblings. Chest. (2003) 123:1527–35. 10.1378/chest.123.5.1527</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.123.5.1527</ArticleId>
            <ArticleId IdType="pubmed">12740270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vihlborg P, Bryngelsson IL, Andersson L, Graff P. Risk of sarcoidosis and seropositive rheumatoid arthritis from occupational silica exposure in Swedish iron foundries: a retrospective cohort study. BMJ Open. (2017) 7:e016839. 10.1136/bmjopen-2017-016839</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2017-016839</ArticleId>
            <ArticleId IdType="pmc">PMC5642773</ArticleId>
            <ArticleId IdType="pubmed">28729325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonsson E, Järvholm B, Andersson M. Silica dust and sarcoidosis in Swedish construction workers. Occup Med. (2019) 69:482–6. 10.1093/occmed/kqz118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/occmed/kqz118</ArticleId>
            <ArticleId IdType="pmc">PMC6913734</ArticleId>
            <ArticleId IdType="pubmed">31504840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronsmans S, Verbeken EK, Adams E, Keirsbilck S, Yserbyt J, Wuyts WA, et al. . Granulomatous lung disease in two workers making light bulbs. Am J Ind Med. (2019) 62:908–3. 10.1002/ajim.23030
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajim.23030</ArticleId>
            <ArticleId IdType="pubmed">31347732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rybicki BA, Amend KL, Maliarik MJ, Iannuzzi MC. Photocopier exposure and risk of sarcoidosis in African-American sibs. Sarcoidosis Vasc Diffuse Lung Dis. (2004) 21:49–55. 10.1007/s11083-004-2862-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11083-004-2862-x</ArticleId>
            <ArticleId IdType="pubmed">15127975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. . World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. (2007) 131:1414–23. 10.1378/chest.06-2114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.06-2114</ArticleId>
            <ArticleId IdType="pubmed">17400664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drent M, Bomans PH, Van Suylen RJ, Lamers RJ, Bast A, Wouters EF. Association of man-made mineral fibre exposure and sarcoidlike granulomas. Respir Med. (2000) 94:815–20. 10.1053/rmed.2000.0827</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/rmed.2000.0827</ArticleId>
            <ArticleId IdType="pubmed">10955759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajdasz DK, Lackland DT, Mohr LC, Judson MA. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol. (2001) 11:111–7. 10.1016/S1047-2797(00)00179-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1047-2797(00)00179-4</ArticleId>
            <ArticleId IdType="pubmed">11164127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima A, Saraya T, Mori T, Ikeda R, Sugita T, Watanabe T, et al. . Familial summer-type hypersensitivity pneumonitis in Japan: two case reports and review of the literature. BMC Res Notes. (2013) 6:371. 10.1186/1756-0500-6-371</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-0500-6-371</ArticleId>
            <ArticleId IdType="pmc">PMC3847446</ArticleId>
            <ArticleId IdType="pubmed">24028200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet. (1996) 348:690. 10.1016/S0140-6736(05)65119-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)65119-7</ArticleId>
            <ArticleId IdType="pubmed">8782783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. (2016) 48:1690–9. 10.1183/13993003.00477-2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00477-2016</ArticleId>
            <ArticleId IdType="pubmed">27471207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawahata M, Sugiyama Y. An epidemiological perspective of the pathology and etiology of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2016) 33:112–6. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27537712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill AB.
The environment and disease: association or causation? (1965). J R Soc Med. (2015). 108:32–7. 10.1177/0141076814562718</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0141076814562718</ArticleId>
            <ArticleId IdType="pmc">PMC4291332</ArticleId>
            <ArticleId IdType="pubmed">25572993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris SS. Vitamin D and African Americans. J Nutr. (2006) 136:1126–9. 10.1093/jn/136.4.1126</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jn/136.4.1126</ArticleId>
            <ArticleId IdType="pubmed">16549493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. (2003) 97:978–82. 10.1016/S0954-6111(03)00127-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0954-6111(03)00127-6</ArticleId>
            <ArticleId IdType="pubmed">12924527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Yibrehu B, Zabini D, Kuebler WM. Animal models of sarcoidosis. Cell Tissue Res. (2017) 367:651–61. 10.1007/s00441-016-2526-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-016-2526-3</ArticleId>
            <ArticleId IdType="pubmed">27807704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barna BP, Judson MA, Thomassen MJ. Carbon Nanotubes and Chronic Granulomatous Disease. Nanomaterials. (2014) 4:508–21. 10.3390/nano4020508</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nano4020508</ArticleId>
            <ArticleId IdType="pmc">PMC4267561</ArticleId>
            <ArticleId IdType="pubmed">25525507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barna BP, Huizar I, Malur A, McPeek M, Marshall I, Jacob M, et al. . Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation. Int J Mol Sci. (2013) 14:23858–71. 10.3390/ijms141223858</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms141223858</ArticleId>
            <ArticleId IdType="pmc">PMC3876082</ArticleId>
            <ArticleId IdType="pubmed">24322444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. . Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. (2010) 181:360–73. 10.1164/rccm.200905-0696OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200905-0696OC</ArticleId>
            <ArticleId IdType="pmc">PMC2822973</ArticleId>
            <ArticleId IdType="pubmed">19910611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herndon B, Quinn T, Wasson N, Nzabi M, Molteni A. Urease and Helicobacter spp. antigens in pulmonary granuloma. J Comp Pathol. (2013) 148:266–77. 10.1016/j.jcpa.2012.06.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcpa.2012.06.011</ArticleId>
            <ArticleId IdType="pubmed">22901429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, Farver CF, et al. . Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol. (2011) 44:166–74. 10.1165/rcmb.2009-0350OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2009-0350OC</ArticleId>
            <ArticleId IdType="pmc">PMC3049230</ArticleId>
            <ArticleId IdType="pubmed">20348207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werner JL, Escolero SG, Hewlett JT, Mak TN, Williams BP, Eishi Y, et al. . Induction of pulmonary granuloma formation by propionibacterium acnes is regulated by MyD88 and Nox2. Am J Respir Cell Mol Biol. (2017) 56:121–30. 10.1165/rcmb.2016-0035OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2016-0035OC</ArticleId>
            <ArticleId IdType="pmc">PMC5248957</ArticleId>
            <ArticleId IdType="pubmed">27607191</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32676081</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Environmental Risk Factors for Sarcoidosis.</ArticleTitle>
        <Pagination>
          <StartPage>1340</StartPage>
          <MedlinePgn>1340</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1340</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.01340</ELocationID>
        <Abstract>
          <AbstractText>Sarcoidosis is a multisystem granulomatous disease that may affect any body organ. Sarcoidosis is associated with many environmental and occupational exposures. Because the exact immunopathogenesis of sarcoidosis is unknown, it is not known whether these exposures are truly causing sarcoidosis, rendering the immune system more susceptible to the development of sarcoidosis, exacerbating subclinical cases of sarcoidosis, or causing a granulomatous condition distinct from sarcoidosis. This manuscript outlines what is known about the immunopathogenesis of sarcoidosis and postulates mechanisms whereby these exposures could cause or exacerbate the disease. We also describe the varied environmental and occupational exposures that have been associated with sarcoidosis. This includes potential infectious exposures such as mycobacteria and Propionibacterium acnes, a skin commensal bacterium, as well as non-infectious environmental exposures including inhaled bioaerosols, metal dusts and products of combustion. Further insights concerning the relationship of environmental exposures to the development of sarcoidosis may have a major impact on the prevention and treatment of this enigmatic disease.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Judson.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Judson</LastName>
            <ForeName>Marc A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Albany Medical College, Albany, NY, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">antigen</Keyword>
        <Keyword MajorTopicYN="Y">environment</Keyword>
        <Keyword MajorTopicYN="Y">immunity</Keyword>
        <Keyword MajorTopicYN="Y">infection</Keyword>
        <Keyword MajorTopicYN="Y">sarcoidosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32676081</ArticleId>
        <ArticleId IdType="pmc">PMC7333358</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2020.01340</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. . Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. (2001) 164(10 Pt 1):1885–9. 10.1164/ajrccm.164.10.2104046</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/ajrccm.164.10.2104046</ArticleId>
            <ArticleId IdType="pubmed">11734441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. (2012) 29:119–27. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23461074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol. (2012) 3:411. 10.3389/fimmu.2012.00411</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2012.00411</ArticleId>
            <ArticleId IdType="pmc">PMC3538277</ArticleId>
            <ArticleId IdType="pubmed">23308075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zumla A, James DG. Granulomatous infections: etiology and classification. Clin Infect Dis. (1996) 23:146–58. 10.1093/clinids/23.1.146</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/clinids/23.1.146</ArticleId>
            <ArticleId IdType="pubmed">8816144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. (2012). 186:314–24. 10.1164/rccm.201203-0513CI</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201203-0513CI</ArticleId>
            <ArticleId IdType="pubmed">22679012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect. (1996) 104(Suppl. 5):945–7. 10.1289/ehp.96104s5945</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1289/ehp.96104s5945</ArticleId>
            <ArticleId IdType="pmc">PMC1469698</ArticleId>
            <ArticleId IdType="pubmed">8933039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. (1997) 336:1224–34. 10.1056/NEJM199704243361706</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199704243361706</ArticleId>
            <ArticleId IdType="pubmed">9110911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. (2011) 183:573–81. 10.1164/rccm.201006-0865CI</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201006-0865CI</ArticleId>
            <ArticleId IdType="pmc">PMC3081278</ArticleId>
            <ArticleId IdType="pubmed">21037016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moller DR, Chen ES. Genetic basis of remitting sarcoidosis: triumph of the trimolecular complex?
Am J Respir Crit Care Med. (2002) 27:391–5. 10.1165/rcmb.2002-0164PS</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2002-0164PS</ArticleId>
            <ArticleId IdType="pubmed">12356571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broos CE, Koth LL, van Nimwegen M, Veen JCCM, Paulissen SMJ, Hamburg JP, et al. . Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J. (2018) 51:170112. 10.1183/13993003.01124-2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01124-2017</ArticleId>
            <ArticleId IdType="pubmed">29449421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis. (2002) 19:83–95. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12102613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du Bois R, Beirne PA, Anevlavis SE.
Genetics. In: Drent M, Costabel U. editors. Sarcoidosis: European Respiratory Monograph.
Sheffield: European respiroatry Society Journals Ltd;  (2005). p. 64–81. 10.1183/1025448x.00032005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/1025448x.00032005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, et al. . HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. (2003) 73:720–35. 10.1086/378097</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/378097</ArticleId>
            <ArticleId IdType="pmc">PMC1180597</ArticleId>
            <ArticleId IdType="pubmed">14508706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer AS, Hamzeh N, Maier LA. Sarcoidosis and chronic beryllium disease: similarities and differences. Semin Respir Crit Care Med. (2014) 35:316–29. 10.1055/s-0034-1377059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0034-1377059</ArticleId>
            <ArticleId IdType="pubmed">25007084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J. (2006) 27:1190–5. 10.1183/09031936.06.00112205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.06.00112205</ArticleId>
            <ArticleId IdType="pubmed">16540500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Fingerlin TE, et al. . Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med. (2011) 183:1680–8. 10.1164/rccm.201002-0254OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201002-0254OC</ArticleId>
            <ArticleId IdType="pmc">PMC3136994</ArticleId>
            <ArticleId IdType="pubmed">21471109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL, et al. . Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occup Environ Med. (2011) 68:842–8. 10.1136/oem.2010.064220</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/oem.2010.064220</ArticleId>
            <ArticleId IdType="pmc">PMC4347849</ArticleId>
            <ArticleId IdType="pubmed">21460389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA. (2000) 97:12717–22. 10.1073/pnas.220430797</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.220430797</ArticleId>
            <ArticleId IdType="pmc">PMC18830</ArticleId>
            <ArticleId IdType="pubmed">11050177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tinkle SS, Schwitters PW, Newman LS. Cytokine production by bronchoalveolar lavage cells in chronic beryllium disease. Environ Health Perspect. (1996) 104(Suppl. 5):969–71. 10.1289/ehp.96104s5969</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1289/ehp.96104s5969</ArticleId>
            <ArticleId IdType="pmc">PMC1469699</ArticleId>
            <ArticleId IdType="pubmed">8933043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James WE, Koutroumpakis E, Saha B, Nathani A, Saavedra L, Yucel RM, et al. . Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest. (2018) 154:349–56. 10.1016/j.chest.2018.02.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2018.02.003</ArticleId>
            <ArticleId IdType="pubmed">29453944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurata A, Terado Y, Izumi M, Fujioka Y, Franke FE. Where does the antigen of cutaneous sarcoidosis come from?
J Cutan Pathol. (2010) 37:211–21. 10.1111/j.1600-0560.2009.01309.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0560.2009.01309.x</ArticleId>
            <ArticleId IdType="pubmed">19615023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bordignon M, Rottoli P, Agostini C, Alaibac M. Adaptive immune responses in primary cutaneous sarcoidosis. Clin Dev Immunol. (2011) 2011:235142. 10.1155/2011/235142</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2011/235142</ArticleId>
            <ArticleId IdType="pmc">PMC3095245</ArticleId>
            <ArticleId IdType="pubmed">21603192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkman CC, Rouhani SJ, Srinivasan N, Engelhard VH. Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells. J Immunol. (2013) 191:2412–25. 10.4049/jimmunol.1300651</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300651</ArticleId>
            <ArticleId IdType="pmc">PMC3796582</ArticleId>
            <ArticleId IdType="pubmed">23926324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judson MA. A sarcoidosis clinician's perspective of MHC functional elements outside the antigen binding site. Hum Immunol. (2019) 80:85–9. 10.1016/j.humimm.2018.05.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humimm.2018.05.007</ArticleId>
            <ArticleId IdType="pubmed">29859205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossman MD, Thompson B, Frederick M, Iannuzzi MC, Rybicki BA, Pander JP, et al. . HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2008) 25:125–32. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19382531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zissel G, Muller-Quernheim J. Specific antigen(s) in sarcoidosis: a link to autoimmunity?
Eur Respir J. (2016) 47:707–9. 10.1183/13993003.01791-2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01791-2015</ArticleId>
            <ArticleId IdType="pubmed">26929312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Häggmark A, Hamsten C, Wiklundh E, Lindskog C, Mattsson C, Andersson E, et al. . Proteomic profiling reveals autoimmune targets in sarcoidosis. Am J Respir Crit Care Med. (2015) 191:574–83. 10.1164/rccm.201407-1341OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201407-1341OC</ArticleId>
            <ArticleId IdType="pubmed">25608002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchernev G, Lotti T, Cardoso JC, Kanazawa N, Guarneri C, Wollina U. Cancer, infection and disturbances of the integrity of tissue homeostasis: the most significant triggers for molecular mimicry and autoimmunity in dermatology?
Wien Med Wochenschr. (2014) 164:245–6. 10.1007/s10354-014-0280-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10354-014-0280-2</ArticleId>
            <ArticleId IdType="pubmed">24796584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchernev G, Wollina U. Bacterial antigens and molecular mimicry: the bridging common problematic link in the pathogenesis of sarcoidosis and sarcoid-like reactions: isn't it time to wake up?
Wien Med Wochenschr. (2014). 164:260–2. 10.1007/s10354-014-0283-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10354-014-0283-z</ArticleId>
            <ArticleId IdType="pubmed">24871544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinloch AJ, Kaiser Y, Wolfgeher D, Ai J, Eklund A, Clark MR, et al. . In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis. Front Immunol. (2018) 9:1516. 10.3389/fimmu.2018.01516</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01516</ArticleId>
            <ArticleId IdType="pmc">PMC6046378</ArticleId>
            <ArticleId IdType="pubmed">30038611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas M, Restrepo-Jimenez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, et al. . Molecular mimicry and autoimmunity. J Autoimmun. (2018) 95:100–23. 10.1016/j.jaut.2018.10.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2018.10.012</ArticleId>
            <ArticleId IdType="pubmed">30509385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grunewald J, Kaiser Y, Ostadkarampour M, Rivera NV, Vezzi F, Lötstedt B, et al. . T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J. (2016) 47:898–909. 10.1183/13993003.01209-2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01209-2015</ArticleId>
            <ArticleId IdType="pubmed">26585430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eberhardt C, Thillai M, Parker R, Siddiqui N, Potiphar L, Goldin R, et al. . Proteomic analysis of kveim reagent identifies targets of cellular immunity in sarcoidosis. PLoS ONE. (2017) 12:e0170285. 10.1371/journal.pone.0170285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0170285</ArticleId>
            <ArticleId IdType="pmc">PMC5256960</ArticleId>
            <ArticleId IdType="pubmed">28114394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heyder T, Kohler M, Tarasova NK, Haag S, Rutishauser D, Rivera NV, et al. . Approach for identifying human leukocyte antigen (HLA)-DR bound peptides from scarce clinical samples. Mol Cell Proteomics. (2016) 15:3017–29. 10.1074/mcp.M116.060764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M116.060764</ArticleId>
            <ArticleId IdType="pmc">PMC5013314</ArticleId>
            <ArticleId IdType="pubmed">27452731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahlström J, Dengjel J, Winqvist O, Targoff I, Persson B, Duyar H, et al. . Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol. (2009) 133:353–63. 10.1016/j.clim.2009.08.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2009.08.008</ArticleId>
            <ArticleId IdType="pubmed">19786367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, et al. . Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. (2007) 117:3576–82. 10.1172/JCI32401</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI32401</ArticleId>
            <ArticleId IdType="pmc">PMC2045606</ArticleId>
            <ArticleId IdType="pubmed">17975675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontenot AP, Falta MT, Kappler JW, Dai S, McKee AS. Beryllium-induced hypersensitivity: genetic susceptibility and neoantigen generation. J Immunol. (2016) 196:22–7. 10.4049/jimmunol.1502011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1502011</ArticleId>
            <ArticleId IdType="pmc">PMC4685955</ArticleId>
            <ArticleId IdType="pubmed">26685315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobak S, Yilmaz H, Sever F, Duran A, Sen N, Karaarslan A. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis. (2014) 2014:351852. 10.1155/2014/351852</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/351852</ArticleId>
            <ArticleId IdType="pmc">PMC4281448</ArticleId>
            <ArticleId IdType="pubmed">25580285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, et al. . Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA. (2005) 102:7922–7. 10.1073/pnas.0501190102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0501190102</ArticleId>
            <ArticleId IdType="pmc">PMC1142372</ArticleId>
            <ArticleId IdType="pubmed">15894616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. (2018) 13:1076–82. 10.1016/j.jtho.2018.04.031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2018.04.031</ArticleId>
            <ArticleId IdType="pubmed">29763666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. . Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. (2017) 82:34–44. 10.1016/j.ejca.2017.05.032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.05.032</ArticleId>
            <ArticleId IdType="pubmed">28646772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. (2018) 9:227–40. 10.1177/2040622318790197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040622318790197</ArticleId>
            <ArticleId IdType="pmc">PMC6196636</ArticleId>
            <ArticleId IdType="pubmed">30364496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossides M, Grunewald J, Eklund A, Kullberg S, Di Giuseppe D, Askling J, et al. . Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. (2018) 52:1800385. 10.1183/13993003.00385-2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00385-2018</ArticleId>
            <ArticleId IdType="pubmed">29946010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin AM, Iannuzzi MC, Montgomery CG, Trudeau S, Datta I, McKeigue P, et al. . Association of ANXA11 genetic variation with sarcoidosis in African Americans and European Americans. Genes Immun. (2013) 14:13–8. 10.1038/gene.2012.48</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gene.2012.48</ArticleId>
            <ArticleId IdType="pmc">PMC3595044</ArticleId>
            <ArticleId IdType="pubmed">23151485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrianto I, Lin CP, Hale JJ, Levin AM, Datta I, Parker R, et al. . Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS ONE. (2012) 7:e43907. 10.1371/journal.pone.0043907</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0043907</ArticleId>
            <ArticleId IdType="pmc">PMC3428296</ArticleId>
            <ArticleId IdType="pubmed">22952805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morais A, Lima B, Peixoto MJ, Alves H, Marques A, Delgado L. BTNL2 gene polymorphism associations with susceptibility and phenotype expression in sarcoidosis. Respir Med. (2012) 106:1771–7. 10.1016/j.rmed.2012.08.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2012.08.009</ArticleId>
            <ArticleId IdType="pubmed">23017494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esteves T, Aparicio G, Garcia-Patos V. Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis. BMC Pulm Med. (2016) 16:165. 10.1186/s12890-016-0332-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12890-016-0332-z</ArticleId>
            <ArticleId IdType="pmc">PMC5126827</ArticleId>
            <ArticleId IdType="pubmed">27894280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang C, Huang H, Xu Z. Immunological evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. PLoS ONE. (2016) 11:e0154716. 10.1371/journal.pone.0154716</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0154716</ArticleId>
            <ArticleId IdType="pmc">PMC4968811</ArticleId>
            <ArticleId IdType="pubmed">27479700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Eom M, Kim SH, Wang HY, Lee H, Choi EH. Identification of Mycobacterium tuberculosis and non-tuberculous mycobacteria from cutaneous sarcoidosis lesions by reverse blot hybridization assay. J Dermatol. (2019) 46:917–21. 10.1111/1346-8138.15042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1346-8138.15042</ArticleId>
            <ArticleId IdType="pubmed">31392741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goyal B, Sheikh JA, Agarwal R, Verma I. Levels of circulating immune complexes containing Mycobacterium Tuberculosis-specific antigens in pulmonary tuberculosis and sarcoidosis patients. Indian J Med Microbiol. (2017) 35:290–2. 10.4103/0255-0857.209569</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0255-0857.209569</ArticleId>
            <ArticleId IdType="pubmed">28681824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotsinger JE, Celada LJ, Polosukhin VV, Atkinson JB, Drake WP. Molecular analysis of sarcoidosis granulomas reveals antimicrobial targets. Am J Respir Cell Mol Biol. (2016) 55:128–34. 10.1165/rcmb.2015-0212OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2015-0212OC</ArticleId>
            <ArticleId IdType="pmc">PMC4942207</ArticleId>
            <ArticleId IdType="pubmed">26807608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T, et al. . Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. (2002) 40:198–204. 10.1128/JCM.40.1.198-204.2002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.40.1.198-204.2002</ArticleId>
            <ArticleId IdType="pmc">PMC120089</ArticleId>
            <ArticleId IdType="pubmed">11773116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milman N, Lisby G, Friis S, Kemp L. Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study. Sarcoidosis Vasc Diffuse Lung Dis. (2004) 21:25–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15127971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. . Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. (2005) 201:755–67. 10.1084/jem.20040429</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20040429</ArticleId>
            <ArticleId IdType="pmc">PMC2212832</ArticleId>
            <ArticleId IdType="pubmed">15753209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ES, Wahlström J, Song Z, Willett MH, Wikén M, Yung RC, et al. . T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. (2008) 181:8784–96. 10.4049/jimmunol.181.12.8784</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.12.8784</ArticleId>
            <ArticleId IdType="pmc">PMC2700300</ArticleId>
            <ArticleId IdType="pubmed">19050300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake WP, Dhason MS, Nadaf M, Shepherd BE, Vadivelu S, Hajizadeh R, et al. . Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun. (2007) 75:527–30. 10.1128/IAI.00732-06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00732-06</ArticleId>
            <ArticleId IdType="pmc">PMC1828402</ArticleId>
            <ArticleId IdType="pubmed">17088357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oswald-Richter KA, Culver DA, Hawkins C, Hajizadeh R, Abraham S, Shepherd BE, et al. . Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. (2009) 77:3740–8. 10.1128/IAI.00142-09</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00142-09</ArticleId>
            <ArticleId IdType="pmc">PMC2738026</ArticleId>
            <ArticleId IdType="pubmed">19596780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homma JY, Abe C, Chosa H, Ueda K, Saegusa J, Nakayama M, et al. . Bacteriological investigation on biopsy specimens from patients with sarcoidosis. Jpn J Exp Med. (1978) 48:251–5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">713130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe C, Iwai K, Mikami R, Hosoda Y. Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A. (1984) 256:541–7. 10.1016/S0174-3031(84)80032-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0174-3031(84)80032-3</ArticleId>
            <ArticleId IdType="pubmed">6377763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagata K, Eishi Y, Uchida K, Yoneda K, Hatanaka H, Yasuhara T, et al. . Immunohistochemical detection of propionibacterium acnes in the retinal granulomas in patients with ocular sarcoidosis. Sci Rep. (2017) 7:15226. 10.1038/s41598-017-15710-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-15710-0</ArticleId>
            <ArticleId IdType="pmc">PMC5680245</ArticleId>
            <ArticleId IdType="pubmed">29123243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki Y, Uchida K, Takemura T, Sekine M, Tamura T, Furukawa A, et al. . Propionibacterium acnes-derived insoluble immune complexes in sinus macrophages of lymph nodes affected by sarcoidosis. PLoS ONE. (2018) 13:e0192408. 10.1371/journal.pone.0192408</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0192408</ArticleId>
            <ArticleId IdType="pmc">PMC5798840</ArticleId>
            <ArticleId IdType="pubmed">29401490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hajizadeh R, Sato H, Carlisle J, Nadaf MT, Evans W, Shepherd BE, et al. . Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol. (2007) 27:445–54. 10.1007/s10875-007-9080-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-007-9080-4</ArticleId>
            <ArticleId IdType="pmc">PMC3962023</ArticleId>
            <ArticleId IdType="pubmed">17357846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A, Zwolska Z, Izycka-Swieszewska E, Augustynowicz-Kopec E, et al. . Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. (2006) 44:3448–51. 10.1128/JCM.01433-06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01433-06</ArticleId>
            <ArticleId IdType="pmc">PMC1594733</ArticleId>
            <ArticleId IdType="pubmed">16954298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, et al. . Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol. (2007) 150:460–8. 10.1111/j.1365-2249.2007.03510.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2007.03510.x</ArticleId>
            <ArticleId IdType="pmc">PMC2219367</ArticleId>
            <ArticleId IdType="pubmed">17924974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakata Y, Ejiri T, Kishi T, Mori Y, Hioka T, Kataoka M, et al. . Alveolar lymphocyte proliferation induced by Propionibacterium acnes in sarcoidosis patients. Acta Med Okayama. (1986) 40:257–64. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3024453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furusawa H, Suzuki Y, Miyazaki Y, Inase N, Eishi Y. Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respir Investig. (2012) 50:104–9. 10.1016/j.resinv.2012.07.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.resinv.2012.07.001</ArticleId>
            <ArticleId IdType="pubmed">23021769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terčelj M, Stopinšek S, Ihan A, Salobir B, Simčič S, Wraber B, et al. . In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis. Clin Exp Immunol. (2011) 166:87–93. 10.1111/j.1365-2249.2011.04456.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2011.04456.x</ArticleId>
            <ArticleId IdType="pmc">PMC3193923</ArticleId>
            <ArticleId IdType="pubmed">21910725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suchankova M, Paulovicova E, Paulovicova L, Majer I, Tedlova E, Novosadova H, et al. . Increased antifungal antibodies in bronchoalveolar lavage fluid and serum in pulmonary sarcoidosis. Scand J Immunol. (2015) 81:259–64. 10.1111/sji.12273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/sji.12273</ArticleId>
            <ArticleId IdType="pubmed">25641379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishihara M, Ohno S, Ono H, Isogai E, Kimura K, Isogai H, et al. . Seroprevalence of anti-Borrelia antibodies among patients with confirmed sarcoidosis in a region of Japan where Lyme borreliosis is endemic. Graefes Arch Clin Exp Ophthalmol. (1998) 236:280–4. 10.1007/s004170050078</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004170050078</ArticleId>
            <ArticleId IdType="pubmed">9561361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Ma D, Luo W, Zhu Y. Detection of Borrelia burgdorferi DNA in granulomatous tissues from patients with sarcoidosis using polymerase chain reaction in situ technique. Chin Med Sci J. (1996) 11:220–3. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9387386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lian W, Luo W. Borrelia burgdorferi DNA in biological samples from patients with sarcoidosis using the polymerase chain reaction technique. Chin Med Sci J. (1995) 10:93–5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7647327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, et al. . Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2013) 30:201–11. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3929334</ArticleId>
            <ArticleId IdType="pubmed">24284293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. . Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. (2013) 149:1040–9. 10.1001/jamadermatol.2013.4646</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2013.4646</ArticleId>
            <ArticleId IdType="pmc">PMC3927541</ArticleId>
            <ArticleId IdType="pubmed">23863960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steen T, English JC. Oral minocycline in treatment of cutaneous sarcoidosis. JAMA Dermatol. (2013) 149:758–60. 10.1001/jamadermatol.2013.2977</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2013.2977</ArticleId>
            <ArticleId IdType="pubmed">23783160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. (2001) 137:69–73. 10.1001/archderm.137.1.69</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archderm.137.1.69</ArticleId>
            <ArticleId IdType="pubmed">11176663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki E, Ando M, Fukami T, Nureki S, Eishi Y, Kumamoto T. Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect?
Clin Rheumatol. (2008) 27:1195–7. 10.1007/s10067-008-0903-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-008-0903-3</ArticleId>
            <ArticleId IdType="pubmed">18458989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takemori N, Nakamura M, Kojima M, Eishi Y. Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. J Med Case Rep. (2014) 8:15. 10.1186/1752-1947-8-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1752-1947-8-15</ArticleId>
            <ArticleId IdType="pmc">PMC3916803</ArticleId>
            <ArticleId IdType="pubmed">24428939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tercelj M, Salobir B, Zupancic M, Rylander R. Antifungal medication is efficient in the treatment of sarcoidosis. Ther Adv Respir Dis. (2011) 5:157–62. 10.1177/1753465811401648</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1753465811401648</ArticleId>
            <ArticleId IdType="pubmed">21436319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inaoka PT, Shono M, Kamada M, Espinoza JL. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci. (2019) 26:45. 10.1186/s12929-019-0537-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12929-019-0537-6</ArticleId>
            <ArticleId IdType="pmc">PMC6558716</ArticleId>
            <ArticleId IdType="pubmed">31182092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinoza JL, Minami M. Sensing bacterial-induced DNA damaging effects via natural killer group 2 member D immune receptor: from dysbiosis to autoimmunity and carcinogenesis. Front Immunol. (2018) 9:52. 10.3389/fimmu.2018.00052</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00052</ArticleId>
            <ArticleId IdType="pmc">PMC5788971</ArticleId>
            <ArticleId IdType="pubmed">29422899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. (2018) 44:34–40. 10.1016/j.mib.2018.07.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mib.2018.07.003</ArticleId>
            <ArticleId IdType="pmc">PMC6435260</ArticleId>
            <ArticleId IdType="pubmed">30036705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa AN, Costa FMD, Campos SV, Salles RK, Athanazio RA. The pulmonary microbiome: challenges of a new paradigm. J Bras Pneumol. (2018) 44:424–32. 10.1590/s1806-37562017000000209</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/s1806-37562017000000209</ArticleId>
            <ArticleId IdType="pmc">PMC6467588</ArticleId>
            <ArticleId IdType="pubmed">30066739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulaiman I, Wu BG, Li Y, Scott AS, Malecha P, Scaglione B, et al. . Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J. (2018) 52:1800810. 10.1183/13993003.00810-2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00810-2018</ArticleId>
            <ArticleId IdType="pubmed">30093571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garzoni C, Brugger SD, Qi W, Wasmer S, Cusini A, Dumont P, et al. . Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax. (2013) 68:1150–6. 10.1136/thoraxjnl-2012-202917</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thoraxjnl-2012-202917</ArticleId>
            <ArticleId IdType="pmc">PMC3841796</ArticleId>
            <ArticleId IdType="pubmed">23945167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke EL, Lauder AP, Hofstaedter CE, Hwang Y, Fitzgerald AS, Imai I, et al. . Microbial Lineages in Sarcoidosis. A Metagenomic Analysis Tailored for Low-Microbial Content Samples. Am J Respir Crit Care Med. (2018) 197:225–34. 10.1164/rccm.201705-0891OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201705-0891OC</ArticleId>
            <ArticleId IdType="pmc">PMC5768903</ArticleId>
            <ArticleId IdType="pubmed">28846439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmermann A, Knecht H, Häsler R, Zissel G, Gaede KI, Hofmann S, et al. . Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota. Eur Respir J. (2017) 50:1600746. 10.1183/13993003.00746-2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00746-2016</ArticleId>
            <ArticleId IdType="pubmed">29242257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scher JU, Joshua V, Artacho A, Abdollahi-Roodsaz S, Öckinger J, Kullberg S, et al. . The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome. (2016) 4:60. 10.1186/s40168-016-0206-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-016-0206-x</ArticleId>
            <ArticleId IdType="pmc">PMC5114783</ArticleId>
            <ArticleId IdType="pubmed">27855721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. (1986) 123:840–5. 10.1093/oxfordjournals.aje.a114313</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a114313</ArticleId>
            <ArticleId IdType="pubmed">3962966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demirkok SS, Basaranoglu M, Coker E, Karayel T. Seasonality of the onset of symptoms, tuberculin test anergy and Kveim positive reaction in a large cohort of patients with sarcoidosis. Respirology. (2007) 12:591–3. 10.1111/j.1440-1843.2007.01062.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1843.2007.01062.x</ArticleId>
            <ArticleId IdType="pubmed">17587428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilsher ML. Seasonal clustering of sarcoidosis presenting with erythema nodosum. Eur Respir J. (1998) 12:1197–9. 10.1183/09031936.98.12051197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.98.12051197</ArticleId>
            <ArticleId IdType="pubmed">9864021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fité E, Alsina JM, Mañá J, Pujol R, Ruiz J, Morera J. Epidemiology of sarcoidosis in Catalonia: 1979-1989. Sarcoidosis Vasc Diffuse Lung Dis. (1996) 13:153–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8893385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta D, Agarwal R, Aggarwal AN. Seasonality of sarcoidosis: the 'heat' is on. Sarcoidosis Vasc Diffuse Lung Dis. (2013) 30:241–3. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24284300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ungprasert P, Crowson CS, Matteson EL. Seasonal variation in incidence of sarcoidosis: a population-based study, 1976-2013. Thorax. (2016) 71:1164–6. 10.1136/thoraxjnl-2016-209032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thoraxjnl-2016-209032</ArticleId>
            <ArticleId IdType="pmc">PMC5316382</ArticleId>
            <ArticleId IdType="pubmed">27539620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson TT, Plant BJ, Henry MT, Bredin CP. Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996-2005. Sarcoidosis Vasc Diffuse Lung Dis. (2010) 27:111–20. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21319593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosoda Y, Sasagawa S, Yamaguchi T. Sarcoidosis and tuberculosis: epidemiological similarities and dissimilarities. A review of a series of studies in a Japanese work population. (1941-1996) and the general population (1959-1984). Sarcoidosis Vasc Diffuse Lung Dis. (2004). 21:85–93. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15281429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonough C, Gray GC. Risk factors for sarcoidosis hospitalization among U.S. Navy and Marine Corps personnel, 1981 to 1995. Mil Med. (2000). 165:630–2. 10.1093/milmed/165.8.630</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/milmed/165.8.630</ArticleId>
            <ArticleId IdType="pubmed">10957860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajdasz DK, Judson MA, Mohr LC, Lackland DT. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am J Epidemiol. (1999) 150:271–8. 10.1093/oxfordjournals.aje.a009998</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a009998</ArticleId>
            <ArticleId IdType="pubmed">10430231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowalska M, Niewiadomska E, Zejda JE. Epidemiology of sarcoidosis recorded in 2006-2010 in the Silesian voivodeship on the basis of routine medical reporting. Ann Agric Environ Med. (2014) 21:55–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24738497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J. (2010) 35:1088–97. 10.1183/09031936.00197808</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00197808</ArticleId>
            <ArticleId IdType="pubmed">19897550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prezant DJ, Dhala A, Goldstein A, Janus D, Ortiz F, Aldrich TK, et al. . The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest. (1999) 116:1183–93. 10.1378/chest.116.5.1183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.116.5.1183</ArticleId>
            <ArticleId IdType="pubmed">10559074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kern DG, Neill MA, Wrenn DS, Varone JC. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis. (1993) 148(4 Pt 1):974–80. 10.1164/ajrccm/148.4_Pt_1.974</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/ajrccm/148.4_Pt_1.974</ArticleId>
            <ArticleId IdType="pubmed">8214953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorham ED, Garland CF, Garland FC, Kaiser K, Travis WD, Centeno JA. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975-2001. Chest. (2004) 126:1431–8. 10.1378/chest.126.5.1431</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.126.5.1431</ArticleId>
            <ArticleId IdType="pubmed">15539709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. . A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. (2004) 170:1324–30. 10.1164/rccm.200402-249OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200402-249OC</ArticleId>
            <ArticleId IdType="pubmed">15347561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, et al. . Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med. (2005) 47:226–34. 10.1097/01.jom.0000155711.88781.91</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.jom.0000155711.88781.91</ArticleId>
            <ArticleId IdType="pubmed">15761318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucera GP, Rybicki BA, Kirkey KL, Coon SW, Major ML, Maliarik MJ, et al. . Occupational risk factors for sarcoidosis in African-American siblings. Chest. (2003) 123:1527–35. 10.1378/chest.123.5.1527</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.123.5.1527</ArticleId>
            <ArticleId IdType="pubmed">12740270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vihlborg P, Bryngelsson IL, Andersson L, Graff P. Risk of sarcoidosis and seropositive rheumatoid arthritis from occupational silica exposure in Swedish iron foundries: a retrospective cohort study. BMJ Open. (2017) 7:e016839. 10.1136/bmjopen-2017-016839</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2017-016839</ArticleId>
            <ArticleId IdType="pmc">PMC5642773</ArticleId>
            <ArticleId IdType="pubmed">28729325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonsson E, Järvholm B, Andersson M. Silica dust and sarcoidosis in Swedish construction workers. Occup Med. (2019) 69:482–6. 10.1093/occmed/kqz118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/occmed/kqz118</ArticleId>
            <ArticleId IdType="pmc">PMC6913734</ArticleId>
            <ArticleId IdType="pubmed">31504840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronsmans S, Verbeken EK, Adams E, Keirsbilck S, Yserbyt J, Wuyts WA, et al. . Granulomatous lung disease in two workers making light bulbs. Am J Ind Med. (2019) 62:908–3. 10.1002/ajim.23030
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajim.23030</ArticleId>
            <ArticleId IdType="pubmed">31347732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rybicki BA, Amend KL, Maliarik MJ, Iannuzzi MC. Photocopier exposure and risk of sarcoidosis in African-American sibs. Sarcoidosis Vasc Diffuse Lung Dis. (2004) 21:49–55. 10.1007/s11083-004-2862-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11083-004-2862-x</ArticleId>
            <ArticleId IdType="pubmed">15127975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. . World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. (2007) 131:1414–23. 10.1378/chest.06-2114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.06-2114</ArticleId>
            <ArticleId IdType="pubmed">17400664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drent M, Bomans PH, Van Suylen RJ, Lamers RJ, Bast A, Wouters EF. Association of man-made mineral fibre exposure and sarcoidlike granulomas. Respir Med. (2000) 94:815–20. 10.1053/rmed.2000.0827</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/rmed.2000.0827</ArticleId>
            <ArticleId IdType="pubmed">10955759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajdasz DK, Lackland DT, Mohr LC, Judson MA. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol. (2001) 11:111–7. 10.1016/S1047-2797(00)00179-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1047-2797(00)00179-4</ArticleId>
            <ArticleId IdType="pubmed">11164127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima A, Saraya T, Mori T, Ikeda R, Sugita T, Watanabe T, et al. . Familial summer-type hypersensitivity pneumonitis in Japan: two case reports and review of the literature. BMC Res Notes. (2013) 6:371. 10.1186/1756-0500-6-371</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-0500-6-371</ArticleId>
            <ArticleId IdType="pmc">PMC3847446</ArticleId>
            <ArticleId IdType="pubmed">24028200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet. (1996) 348:690. 10.1016/S0140-6736(05)65119-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)65119-7</ArticleId>
            <ArticleId IdType="pubmed">8782783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. (2016) 48:1690–9. 10.1183/13993003.00477-2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00477-2016</ArticleId>
            <ArticleId IdType="pubmed">27471207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawahata M, Sugiyama Y. An epidemiological perspective of the pathology and etiology of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2016) 33:112–6. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27537712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill AB.
The environment and disease: association or causation? (1965). J R Soc Med. (2015). 108:32–7. 10.1177/0141076814562718</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0141076814562718</ArticleId>
            <ArticleId IdType="pmc">PMC4291332</ArticleId>
            <ArticleId IdType="pubmed">25572993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris SS. Vitamin D and African Americans. J Nutr. (2006) 136:1126–9. 10.1093/jn/136.4.1126</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jn/136.4.1126</ArticleId>
            <ArticleId IdType="pubmed">16549493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. (2003) 97:978–82. 10.1016/S0954-6111(03)00127-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0954-6111(03)00127-6</ArticleId>
            <ArticleId IdType="pubmed">12924527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Yibrehu B, Zabini D, Kuebler WM. Animal models of sarcoidosis. Cell Tissue Res. (2017) 367:651–61. 10.1007/s00441-016-2526-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-016-2526-3</ArticleId>
            <ArticleId IdType="pubmed">27807704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barna BP, Judson MA, Thomassen MJ. Carbon Nanotubes and Chronic Granulomatous Disease. Nanomaterials. (2014) 4:508–21. 10.3390/nano4020508</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nano4020508</ArticleId>
            <ArticleId IdType="pmc">PMC4267561</ArticleId>
            <ArticleId IdType="pubmed">25525507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barna BP, Huizar I, Malur A, McPeek M, Marshall I, Jacob M, et al. . Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation. Int J Mol Sci. (2013) 14:23858–71. 10.3390/ijms141223858</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms141223858</ArticleId>
            <ArticleId IdType="pmc">PMC3876082</ArticleId>
            <ArticleId IdType="pubmed">24322444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. . Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. (2010) 181:360–73. 10.1164/rccm.200905-0696OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200905-0696OC</ArticleId>
            <ArticleId IdType="pmc">PMC2822973</ArticleId>
            <ArticleId IdType="pubmed">19910611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herndon B, Quinn T, Wasson N, Nzabi M, Molteni A. Urease and Helicobacter spp. antigens in pulmonary granuloma. J Comp Pathol. (2013) 148:266–77. 10.1016/j.jcpa.2012.06.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcpa.2012.06.011</ArticleId>
            <ArticleId IdType="pubmed">22901429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, Farver CF, et al. . Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol. (2011) 44:166–74. 10.1165/rcmb.2009-0350OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2009-0350OC</ArticleId>
            <ArticleId IdType="pmc">PMC3049230</ArticleId>
            <ArticleId IdType="pubmed">20348207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werner JL, Escolero SG, Hewlett JT, Mak TN, Williams BP, Eishi Y, et al. . Induction of pulmonary granuloma formation by propionibacterium acnes is regulated by MyD88 and Nox2. Am J Respir Cell Mol Biol. (2017) 56:121–30. 10.1165/rcmb.2016-0035OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2016-0035OC</ArticleId>
            <ArticleId IdType="pmc">PMC5248957</ArticleId>
            <ArticleId IdType="pubmed">27607191</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
